Clinical Trial Finder

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Study Purpose

This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck cancer that has spread to other places in the body (metastatic or advanced stage) or has come back after prior treatment (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Cisplatin and carboplatin are in a class of chemotherapy medications known as platinum-containing compounds. They work by killing, stopping, or slowing the growth of cancer cells. Docetaxel is in a class of chemotherapy medications called taxanes. It stops cancer cells from growing and dividing and may kill them. The addition of bevacizumab to standard chemotherapy or combination therapy with bevacizumab and atezolizumab may be better than standard chemotherapy plus cetuximab in treating patients with recurrent/metastatic head and neck cancers.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

 No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

 Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patient must have histologically confirmed squamous cell carcinoma of the head and neck (HNSCC) (excluding SCC of salivary glands, Epstein-Barr virus [EBV]-associated nasopharynx and skin) - Patient must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.
Measurements must be obtained within 4 weeks prior to randomization.
  • - Patient must be >= 18 years of age.
  • - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • - Patient must have disease progression after prior therapy with an immune checkpoint inhibitor (ICI) in the first-line setting for recurrent/metastatic disease.
Patient must have received first-line immune checkpoint inhibition for at least 6 weeks. Patients who have recurred or progressed within 12 weeks of immune checkpoint inhibition administered in the definitive setting for locally advanced disease (for e.g., in the context of a clinical trial) will also be eligible if local therapies are not feasible.
  • - Prior combination immunotherapies are permitted, but patient must not have had prior antiangiogenic treatment (e.g., bevacizumab, ziv-aflibercept, ramucirumab, sorafenib, sunitinib, pazopanib, regorafenib, lenvatinib, etc.).
Patient must have completed any prior investigational therapy at least 28 days prior to randomization. NOTE: Patients who received platinum/taxanes in the locally-advanced or recurrent/metastatic setting and did not progress for at least 4 months thereafter, will be eligible for this study. Patients who received cetuximab in the locally-advanced setting and did not progress for at least 4 months thereafter, will also be eligible for this study.
  • - Patient must not have a history of >= grade 3 immune-related adverse event on prior ICI therapy (except those that could be managed with steroids [e.g., dermatologic toxicity, asymptomatic elevation of pancreatic enzymes, etc.]) and ICI could eventually be resumed.
Patients who developed grade 3 endocrinopathies but are now stable on hormone supplementation and/or a daily prednisone dose of =< 10 mg (or equivalent doses of another glucocorticoid), will be permitted on this trial.
  • - Patient must not have a history of PD-1 inhibitor-induced hyper-progression, defined as 100% increase in tumor burden within 8 weeks (or 50% within 4 weeks) of initiating ICI and associated with clinical deterioration.
  • - Patient must not have any of the following criteria due to the possibility of increased risk for tumor bleeding with bevacizumab therapy: - Prior carotid bleeding, - Tumors that invade major vessels (e.g., the carotid) as shown unequivocally by imaging studies, - Central (e.g., within 2 cm from the hilum) lung metastases that are cavitary as shown unequivocally by imaging studies, - Any prior history of bleeding related to the current head and neck cancer, - History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per episode of coughing) within 3 months prior to randomization.
  • - Patient must not have uncontrolled hypertension, a history of hypertensive crisis or hypertensive encephalopathy, or a history of grade 4 thromboembolism.
  • - Patient must not have a history of coagulopathy or hemorrhagic disorders.
  • - Patient must not have a history of thrombosis (e.g., pulmonary embolism or deep venous thrombosis) currently requiring therapeutic anticoagulation (prophylactic use of anticoagulation is allowed) - Patient must not be receiving chronic daily treatment with aspirin (> 325 mg/day) or non-steroidal anti-inflammatory agents (NSAID's) known to inhibit platelet function.
The use of anti-platelet agents [e.g., dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix)] is allowed only if patient is not receiving concurrent aspirin or NSAID's known to inhibit platelet function.
  • - Patient must have PD-L1 expression >= 1% by combined positive score (CPS) in the tumor and/or immune cells.
  • - NOTE: Enrolling centers should test for PD-L1 CPS preferably using the SP263 assay.
Where this is not feasible, using their preferred Clinical Laboratory Improvement Act (CLIA)-certified or similar assay will be accepted. It is preferred for standard of care (SOC) PD-L1 assessments to be done on post-first line ICI samples if available, but SOC PD-L1 assessments on pre-ICI samples will be accepted for eligibility.
  • - Patient must not have a severe infection within 4 weeks prior to randomization, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.
Patients must not have active tuberculosis.
  • - Patient must not have a history of non-infectious pneumonitis requiring steroids at doses greater than or equal to 10 mg per day of prednisone or the equivalent on first line immunotherapy.
  • - Patient must not have a history of solid organ transplantation or stem-cell transplant.
  • - Patient must not be on immunosuppressive medication within 7 days prior to randomization except for: intranasal, inhaled, or topical steroids, local steroid injection, systemic corticosteroids at doses less than or equal to 10 mg per day of prednisone or the equivalent, or steroids used as premedication for hypersensitivity reactions.
  • - Patient must not have an active autoimmune disease that requires systemic treatment within 2 years prior to randomization.
Patients who are receiving replacement therapy for adrenal or pituitary insufficiency will not be excluded.
  • - Patient must not have had a severe hypersensitivity reaction to any of the drug components used on this protocol or to chimeric or humanized antibodies or fusion proteins.
  • - Patient must not have received any live vaccine within 30 days prior to randomization and while participating in the study (and continue for 5 months after the last dose of atezolizumab on Arm C).
Live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Patients are permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and coronavirus disease 2019 (COVID-19) (Note: intranasal influenza vaccines, such as Flu-Mist (registered trademark) are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily, in order to minimize an overlap of adverse events.
  • - Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
  • - All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy.
  • - A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) - Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of protocol treatment for patients assigned to Arms B or C.
  • - NOTE: Patients must also not breastfeed while on treatment and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of treatment for patients assigned to Arms B or C.
  • - Patient must have the ability to understand and the willingness to sign a written informed consent document.
Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible.
  • - Leukocytes >= 3,000/mcL (must be obtained =< 14 days prior to protocol randomization) - Absolute neutrophil count (ANC) >= 1,500/mcL (must be obtained =< 14 days prior to protocol randomization) - Platelets >= 100,000/mcL (must be obtained =< 14 days prior to protocol randomization) - Hemoglobin (Hgb) > 9 g/dL (must be obtained =< 14 days prior to protocol randomization) (Note: Patient may be transfused to meet this criteria) - Total bilirubin =< 2.0 x institutional upper limit of normal (ULN) (=< 5.0 x institutional ULN if hepatic metastases present or =< 3 x ULN for patients with known Gilbert's disease) (must be obtained =< 14 days prior to protocol randomization) - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic metastases present) (must be obtained =< 14 days prior to protocol randomization) - Alkaline phosphatase < 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic or bone metastases present) (must be obtained =< 14 days prior to protocol randomization) - Creatinine =< 1.5 x institutional ULN (must be obtained =< 14 days prior to protocol randomization) - Patients with uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN) must have their calcium levels corrected prior to randomization.
  • - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial.
  • - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured.
For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • - Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.
Patients must not have untreated brain metastases or leptomeningeal disease.
  • - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
  • - Patients must not have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).
Patients may have indwelling catheters (e.g., PleurX [registered trademark])
  • - Patient must not have significant cardiovascular disease (such as New York Heart Association class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to randomization, or unstable arrhythmia or unstable angina at the time of randomization.
  • - Patient must not receive any other chemotherapy, immunotherapy, antitumor hormonal therapy (excluding contraceptives and replacement steroids), radiation therapy, or experimental medications while on protocol treatment.
Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomization and patients must be recovered from the effects of radiation (there is no required minimum recovery period.
  • - Patient must not have had a surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to randomization, or anticipation of need for major surgical procedure while on protocol treatment.
  • - Patient must not have any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of the agents used in this protocol, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.
- Patient must not have a history of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to randomization

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

 NCT05063552
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

 Phase 2/Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

 National Cancer Institute (NCI)
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

 Aarti Bhatia
Principal Investigator Affiliation ECOG-ACRIN Cancer Research Group
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

 NIH
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

 Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Additional Details

PRIMARY OBJECTIVES:

  • I. To evaluate progression-free survival (PFS) of patients treated with chemotherapy plus cetuximab, chemotherapy plus bevacizumab, and atezolizumab plus bevacizumab.
(Phase II)
  • II. To evaluate the overall survival (OS) of patients treated with chemotherapy plus cetuximab to the superior arm from the phase II portion of the protocol.
(Phase III) SECONDARY OBJECTIVES:
  • I. To evaluate the OS for the subset of patients with high PD-L1 expression, defined as combined positive score (CPS) >= 20% on all arms of treatment.
  • II. To evaluate the toxicity of each arm of treatment.
IMAGING OBJECTIVES:
  • I. To establish the correlation between fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and computed tomography (CT) neck imaging biomarkers (maximum standard uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG], tumor volume) and expression of PD-L1 expression (Low versus high, defined as CPS < 20 versus CPS >= 20).
  • II. To determine if 18FDG-PET/CT and CT neck imaging biomarkers at baseline will predict treatment response at nine to twelve weeks post the initiation of treatment, PFS, and OS.
EXPLORATORY OBJECTIVE:
  • I. To establish the correlation between 18F-FDG PET and CT neck radiomics features and PD-L1 expressions (Low versus high - defined as CPS < 20 versus CPS >= 20).
OUTLINE: This is a randomized phase II trial followed by a randomized phase III trial. PHASE II: Patients are randomized to 1 of 3 arms. ARM A: Patients receive cetuximab intravenously (IV) over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or magnetic resonance imaging (MRI) throughout the trial. Patients may undergo echocardiography (ECHO) during screening. ARM B: Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. ARM C: Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. PHASE III: Patients are randomized to 1 of 2 arms. ARM A: Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. ARM B: Patients receive treatment as in Arm B or C above based on results of the Phase II trial. Patients undergo blood sample collection throughout the study. After completion of study treatment, patients are followed up at 30 days and then every 3 months if patient is < 2 years from randomization and every 6 months if patient is 2-5 years from randomization.

Arms & Interventions

Arms

Active Comparator: Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)

Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study.

Experimental: Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)

Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study.

Experimental: Phase II, Arm C (Bevacizumab, Atezolizumab)

Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study.

Experimental: Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)

Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study.

Experimental: Phase III, Arm B (Chemotherapy, Bevacizumab, Atezolizumab)

Patients receive treatment as in Arm B or C above based on results of the Phase II trial.

Interventions

Biological: - Atezolizumab

Given IV

Biological: - Bevacizumab

Given IV

Procedure: - Biospecimen Collection

Undergo blood sample collection

Drug: - Carboplatin

Given IV

Biological: - Cetuximab

Given IV

Drug: - Cisplatin

Given IV

Procedure: - Computed Tomography

Undergo CT scan

Drug: - Docetaxel

Given IV

Procedure: - Echocardiography

Undergo ECHO

Procedure: - Magnetic Resonance Imaging

Undergo MRI

Procedure: - Positron Emission Tomography

Undergo PET scan

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Little Rock, Arkansas

Status

Active, not recruiting

Address

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205

Epic Care-Dublin, Dublin, California

Status

Active, not recruiting

Address

Epic Care-Dublin

Dublin, California, 94568

Epic Care Partners in Cancer Care, Emeryville, California

Status

Active, not recruiting

Address

Epic Care Partners in Cancer Care

Emeryville, California, 94608

Contra Costa Regional Medical Center, Martinez, California

Status

Active, not recruiting

Address

Contra Costa Regional Medical Center

Martinez, California, 94553-3156

Stanford Cancer Institute Palo Alto, Palo Alto, California

Status

Recruiting

Address

Stanford Cancer Institute Palo Alto

Palo Alto, California, 94304

Site Contact

Site Public Contact

[email protected]

650-498-7061

VA Palo Alto Health Care System, Palo Alto, California

Status

Recruiting

Address

VA Palo Alto Health Care System

Palo Alto, California, 94304

Site Contact

Site Public Contact

800-455-0057

Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut

Status

Suspended

Address

Smilow Cancer Hospital-Derby Care Center

Derby, Connecticut, 06418

Fairfield, Connecticut

Status

Recruiting

Address

Smilow Cancer Hospital Care Center-Fairfield

Fairfield, Connecticut, 06824

Site Contact

Site Public Contact

[email protected]

203-785-5702

Glastonbury, Connecticut

Status

Recruiting

Address

Smilow Cancer Hospital Care Center at Glastonbury

Glastonbury, Connecticut, 06033

Site Contact

Site Public Contact

[email protected]

203-785-5702

Greenwich, Connecticut

Status

Suspended

Address

Smilow Cancer Hospital Care Center at Greenwich

Greenwich, Connecticut, 06830

Guilford, Connecticut

Status

Suspended

Address

Smilow Cancer Hospital Care Center - Guilford

Guilford, Connecticut, 06437

Hartford, Connecticut

Status

Recruiting

Address

Smilow Cancer Hospital Care Center at Saint Francis

Hartford, Connecticut, 06105

Site Contact

Site Public Contact

[email protected]

203-785-5702

Yale University, New Haven, Connecticut

Status

Recruiting

Address

Yale University

New Haven, Connecticut, 06520

Site Contact

Site Public Contact

[email protected]

203-785-5702

North Haven, Connecticut

Status

Recruiting

Address

Yale-New Haven Hospital North Haven Medical Center

North Haven, Connecticut, 06473

Site Contact

Site Public Contact

[email protected]

203-785-5702

Orange, Connecticut

Status

Recruiting

Address

Smilow Cancer Hospital-Orange Care Center

Orange, Connecticut, 06477

Site Contact

Site Public Contact

[email protected]

203-785-5702

Stamford, Connecticut

Status

Suspended

Address

Smilow Cancer Hospital Care Center at Long Ridge

Stamford, Connecticut, 06902

Torrington, Connecticut

Status

Suspended

Address

Smilow Cancer Hospital-Torrington Care Center

Torrington, Connecticut, 06790

Trumbull, Connecticut

Status

Recruiting

Address

Smilow Cancer Hospital Care Center-Trumbull

Trumbull, Connecticut, 06611

Site Contact

Site Public Contact

[email protected]

203-785-5702

Waterbury, Connecticut

Status

Suspended

Address

Smilow Cancer Hospital-Waterbury Care Center

Waterbury, Connecticut, 06708

Waterford, Connecticut

Status

Recruiting

Address

Smilow Cancer Hospital Care Center - Waterford

Waterford, Connecticut, 06385

Site Contact

Site Public Contact

[email protected]

203-785-5702

Helen F Graham Cancer Center, Newark, Delaware

Status

Recruiting

Address

Helen F Graham Cancer Center

Newark, Delaware, 19713

Site Contact

Site Public Contact

[email protected]

302-623-4450

Newark, Delaware

Status

Recruiting

Address

Medical Oncology Hematology Consultants PA

Newark, Delaware, 19713

Site Contact

Site Public Contact

[email protected]

302-623-4450

MedStar Washington Hospital Center, Washington, District of Columbia

Status

Recruiting

Address

MedStar Washington Hospital Center

Washington, District of Columbia, 20010

Site Contact

Site Public Contact

202-877-8839

Coral Gables, Florida

Status

Recruiting

Address

UM Sylvester Comprehensive Cancer Center at Coral Gables

Coral Gables, Florida, 33146

Site Contact

Site Public Contact

305-243-2647

Deerfield Beach, Florida

Status

Recruiting

Address

UM Sylvester Comprehensive Cancer Center at Deerfield Beach

Deerfield Beach, Florida, 33442

Site Contact

Site Public Contact

305-243-2647

Broward Health Medical Center, Fort Lauderdale, Florida

Status

Recruiting

Address

Broward Health Medical Center

Fort Lauderdale, Florida, 33316

Site Contact

Site Public Contact

[email protected]

302-651-5572

Miami, Florida

Status

Recruiting

Address

University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136

Site Contact

Site Public Contact

305-243-2647

Miami, Florida

Status

Recruiting

Address

UM Sylvester Comprehensive Cancer Center at Kendall

Miami, Florida, 33176

Site Contact

Site Public Contact

305-243-2647

Plantation, Florida

Status

Recruiting

Address

UM Sylvester Comprehensive Cancer Center at Plantation

Plantation, Florida, 33324

Site Contact

Site Public Contact

305-243-2647

Emory University Hospital Midtown, Atlanta, Georgia

Status

Recruiting

Address

Emory University Hospital Midtown

Atlanta, Georgia, 30308

Site Contact

Site Public Contact

888-946-7447

Atlanta, Georgia

Status

Recruiting

Address

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322

Site Contact

Site Public Contact

404-778-1868

Hawaii Cancer Care - Westridge, 'Aiea, Hawaii

Status

Recruiting

Address

Hawaii Cancer Care - Westridge

'Aiea, Hawaii, 96701

Site Contact

Site Public Contact

[email protected]

808-539-2273

Honolulu, Hawaii

Status

Recruiting

Address

Hawaii Cancer Care Inc - Waterfront Plaza

Honolulu, Hawaii, 96813

Site Contact

Site Public Contact

[email protected]

808-524-6115

Queen's Cancer Cenrer - POB I, Honolulu, Hawaii

Status

Recruiting

Address

Queen's Cancer Cenrer - POB I

Honolulu, Hawaii, 96813

Site Contact

Site Public Contact

808-532-0315

Queen's Medical Center, Honolulu, Hawaii

Status

Recruiting

Address

Queen's Medical Center

Honolulu, Hawaii, 96813

Site Contact

Site Public Contact

808-545-8548

Queen's Cancer Center - Kuakini, Honolulu, Hawaii

Status

Recruiting

Address

Queen's Cancer Center - Kuakini

Honolulu, Hawaii, 96817

Site Contact

Site Public Contact

808-531-8521

Saint Luke's Cancer Institute - Boise, Boise, Idaho

Status

Recruiting

Address

Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712

Site Contact

Site Public Contact

[email protected]

208-381-2774

Fruitland, Idaho

Status

Recruiting

Address

Saint Luke's Cancer Institute - Fruitland

Fruitland, Idaho, 83619

Site Contact

Site Public Contact

[email protected]

208-381-2774

Saint Luke's Cancer Institute - Meridian, Meridian, Idaho

Status

Recruiting

Address

Saint Luke's Cancer Institute - Meridian

Meridian, Idaho, 83642

Site Contact

Site Public Contact

[email protected]

208-381-2774

Saint Luke's Cancer Institute - Nampa, Nampa, Idaho

Status

Recruiting

Address

Saint Luke's Cancer Institute - Nampa

Nampa, Idaho, 83686

Site Contact

Site Public Contact

[email protected]

208-381-2774

Twin Falls, Idaho

Status

Recruiting

Address

Saint Luke's Cancer Institute - Twin Falls

Twin Falls, Idaho, 83301

Site Contact

Site Public Contact

[email protected]

208-381-2774

Rush - Copley Medical Center, Aurora, Illinois

Status

Recruiting

Address

Rush - Copley Medical Center

Aurora, Illinois, 60504

Site Contact

Site Public Contact

[email protected]

630-978-6212

Chicago, Illinois

Status

Recruiting

Address

John H Stroger Jr Hospital of Cook County

Chicago, Illinois, 60612

Site Contact

Site Public Contact

312-864-5204

University of Illinois, Chicago, Illinois

Status

Recruiting

Address

University of Illinois

Chicago, Illinois, 60612

Site Contact

Site Public Contact

312-355-3046

Chicago, Illinois

Status

Recruiting

Address

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

Site Contact

Site Public Contact

[email protected]

773-702-8222

Carle at The Riverfront, Danville, Illinois

Status

Recruiting

Address

Carle at The Riverfront

Danville, Illinois, 61832

Site Contact

Site Public Contact

[email protected]

800-446-5532

Carle Physician Group-Effingham, Effingham, Illinois

Status

Recruiting

Address

Carle Physician Group-Effingham

Effingham, Illinois, 62401

Site Contact

Site Public Contact

[email protected]

800-446-5532

Ingalls Memorial Hospital, Harvey, Illinois

Status

Recruiting

Address

Ingalls Memorial Hospital

Harvey, Illinois, 60426

Site Contact

Site Public Contact

[email protected]

708-915-4673

Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois

Status

Recruiting

Address

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938

Site Contact

Site Public Contact

[email protected]

800-446-5532

New Lenox, Illinois

Status

Recruiting

Address

UC Comprehensive Cancer Center at Silver Cross

New Lenox, Illinois, 60451

Site Contact

Site Public Contact

[email protected]

773-702-8222

Orland Park, Illinois

Status

Recruiting

Address

University of Chicago Medicine-Orland Park

Orland Park, Illinois, 60462

Site Contact

Site Public Contact

[email protected]

773-702-8222

Carle Cancer Center, Urbana, Illinois

Status

Recruiting

Address

Carle Cancer Center

Urbana, Illinois, 61801

Site Contact

Site Public Contact

[email protected]

800-446-5532

Rush-Copley Healthcare Center, Yorkville, Illinois

Status

Recruiting

Address

Rush-Copley Healthcare Center

Yorkville, Illinois, 60560

Site Contact

Site Public Contact

[email protected]

630-978-6212

Mary Greeley Medical Center, Ames, Iowa

Status

Recruiting

Address

Mary Greeley Medical Center

Ames, Iowa, 50010

Site Contact

Site Public Contact

515-956-4132

McFarland Clinic - Ames, Ames, Iowa

Status

Recruiting

Address

McFarland Clinic - Ames

Ames, Iowa, 50010

Site Contact

Site Public Contact

[email protected]

515-239-4734

Mission Cancer and Blood - Ankeny, Ankeny, Iowa

Status

Recruiting

Address

Mission Cancer and Blood - Ankeny

Ankeny, Iowa, 50023

Site Contact

Site Public Contact

515-282-2921

McFarland Clinic - Boone, Boone, Iowa

Status

Recruiting

Address

McFarland Clinic - Boone

Boone, Iowa, 50036

Site Contact

Site Public Contact

515-956-4132

Mercy Cancer Center-West Lakes, Clive, Iowa

Status

Recruiting

Address

Mercy Cancer Center-West Lakes

Clive, Iowa, 50325

Site Contact

Site Public Contact

[email protected]

515-358-6613

Clive, Iowa

Status

Recruiting

Address

Mission Cancer and Blood - West Des Moines

Clive, Iowa, 50325

Site Contact

Site Public Contact

515-241-3305

Greater Regional Medical Center, Creston, Iowa

Status

Recruiting

Address

Greater Regional Medical Center

Creston, Iowa, 50801

Site Contact

Site Public Contact

[email protected]

515-358-6613

Iowa Methodist Medical Center, Des Moines, Iowa

Status

Recruiting

Address

Iowa Methodist Medical Center

Des Moines, Iowa, 50309

Site Contact

Site Public Contact

515-241-6727

Mission Cancer and Blood - Des Moines, Des Moines, Iowa

Status

Recruiting

Address

Mission Cancer and Blood - Des Moines

Des Moines, Iowa, 50309

Site Contact

Site Public Contact

515-241-3305

Mercy Medical Center - Des Moines, Des Moines, Iowa

Status

Recruiting

Address

Mercy Medical Center - Des Moines

Des Moines, Iowa, 50314

Site Contact

Site Public Contact

[email protected]

515-358-6613

Mission Cancer and Blood - Laurel, Des Moines, Iowa

Status

Recruiting

Address

Mission Cancer and Blood - Laurel

Des Moines, Iowa, 50314

Site Contact

Site Public Contact

515-241-3305

McFarland Clinic - Trinity Cancer Center, Fort Dodge, Iowa

Status

Recruiting

Address

McFarland Clinic - Trinity Cancer Center

Fort Dodge, Iowa, 50501

Site Contact

Site Public Contact

515-956-4132

McFarland Clinic - Jefferson, Jefferson, Iowa

Status

Recruiting

Address

McFarland Clinic - Jefferson

Jefferson, Iowa, 50129

Site Contact

Site Public Contact

515-956-4132

McFarland Clinic - Marshalltown, Marshalltown, Iowa

Status

Recruiting

Address

McFarland Clinic - Marshalltown

Marshalltown, Iowa, 50158

Site Contact

Site Public Contact

515-956-4132

Mercy Medical Center-West Lakes, West Des Moines, Iowa

Status

Recruiting

Address

Mercy Medical Center-West Lakes

West Des Moines, Iowa, 50266

Site Contact

Site Public Contact

[email protected]

515-358-6613

Baltimore, Maryland

Status

Recruiting

Address

University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, 21201

Site Contact

Site Public Contact

800-888-8823

Greater Baltimore Medical Center, Baltimore, Maryland

Status

Recruiting

Address

Greater Baltimore Medical Center

Baltimore, Maryland, 21204

Site Contact

Site Public Contact

443-849-3706

Baltimore, Maryland

Status

Recruiting

Address

Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287

Site Contact

Site Public Contact

[email protected]

410-955-8804

UPMC Western Maryland, Cumberland, Maryland

Status

Recruiting

Address

UPMC Western Maryland

Cumberland, Maryland, 21502

Site Contact

Site Public Contact

240-964-1400

Worcester, Massachusetts

Status

Recruiting

Address

UMass Memorial Medical Center - University Campus

Worcester, Massachusetts, 01655

Site Contact

Site Public Contact

[email protected]

508-856-3216

Mercy Hospital, Coon Rapids, Minnesota

Status

Recruiting

Address

Mercy Hospital

Coon Rapids, Minnesota, 55433

Site Contact

Site Public Contact

[email protected]

952-993-1517

Abbott-Northwestern Hospital, Minneapolis, Minnesota

Status

Recruiting

Address

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407

Site Contact

Site Public Contact

[email protected]

952-993-1517

Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota

Status

Recruiting

Address

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416

Site Contact

Site Public Contact

[email protected]

952-993-1517

Regions Hospital, Saint Paul, Minnesota

Status

Recruiting

Address

Regions Hospital

Saint Paul, Minnesota, 55101

Site Contact

Site Public Contact

[email protected]

952-993-1517

Lebanon, New Hampshire

Status

Suspended

Address

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Lebanon, New Hampshire, 03756

University of New Mexico Cancer Center, Albuquerque, New Mexico

Status

Recruiting

Address

University of New Mexico Cancer Center

Albuquerque, New Mexico, 87106

Site Contact

Site Public Contact

[email protected]

505-925-0348

Memorial Medical Center - Las Cruces, Las Cruces, New Mexico

Status

Recruiting

Address

Memorial Medical Center - Las Cruces

Las Cruces, New Mexico, 88011

Site Contact

Site Public Contact

[email protected]

575-556-6545

Clinton, North Carolina

Status

Recruiting

Address

Southeastern Medical Oncology Center-Clinton

Clinton, North Carolina, 28328

Site Contact

Site Public Contact

[email protected]

919-587-9084

Goldsboro, North Carolina

Status

Recruiting

Address

Southeastern Medical Oncology Center-Goldsboro

Goldsboro, North Carolina, 27534

Site Contact

Site Public Contact

[email protected]

919-587-9084

Jacksonville, North Carolina

Status

Recruiting

Address

Southeastern Medical Oncology Center-Jacksonville

Jacksonville, North Carolina, 28546

Site Contact

Site Public Contact

[email protected]

910-587-9084

Miami Valley Hospital South, Centerville, Ohio

Status

Recruiting

Address

Miami Valley Hospital South

Centerville, Ohio, 45459

Site Contact

Site Public Contact

[email protected]

937-528-2900

Miami Valley Hospital, Dayton, Ohio

Status

Recruiting

Address

Miami Valley Hospital

Dayton, Ohio, 45409

Site Contact

Site Public Contact

[email protected]

937-528-2900

Premier Blood and Cancer Center, Dayton, Ohio

Status

Recruiting

Address

Premier Blood and Cancer Center

Dayton, Ohio, 45409

Site Contact

Site Public Contact

937-276-8320

Dayton Physician LLC - Englewood, Dayton, Ohio

Status

Recruiting

Address

Dayton Physician LLC - Englewood

Dayton, Ohio, 45415

Site Contact

Site Public Contact

[email protected]

937-528-2900

Miami Valley Hospital North, Dayton, Ohio

Status

Recruiting

Address

Miami Valley Hospital North

Dayton, Ohio, 45415

Site Contact

Site Public Contact

[email protected]

937-528-2900

Franklin, Ohio

Status

Recruiting

Address

Atrium Medical Center-Middletown Regional Hospital

Franklin, Ohio, 45005-1066

Site Contact

Site Public Contact

[email protected]

937-528-2900

Miami Valley Cancer Care and Infusion, Greenville, Ohio

Status

Recruiting

Address

Miami Valley Cancer Care and Infusion

Greenville, Ohio, 45331

Site Contact

Site Public Contact

937-569-7515

Kettering Medical Center, Kettering, Ohio

Status

Recruiting

Address

Kettering Medical Center

Kettering, Ohio, 45429

Site Contact

Site Public Contact

[email protected]

937-528-2900

Trinity's Tony Teramana Cancer Center, Steubenville, Ohio

Status

Recruiting

Address

Trinity's Tony Teramana Cancer Center

Steubenville, Ohio, 43952

Site Contact

Site Public Contact

888-874-7000

Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio

Status

Recruiting

Address

Toledo Clinic Cancer Centers-Toledo

Toledo, Ohio, 43623

Site Contact

Site Public Contact

800-444-3561

Upper Valley Medical Center, Troy, Ohio

Status

Recruiting

Address

Upper Valley Medical Center

Troy, Ohio, 45373

Site Contact

Site Public Contact

[email protected]

937-528-2900

Oklahoma City, Oklahoma

Status

Recruiting

Address

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Site Contact

Site Public Contact

[email protected]

405-271-8777

Clackamas, Oregon

Status

Suspended

Address

Providence Cancer Institute Clackamas Clinic

Clackamas, Oregon, 97015

Providence Newberg Medical Center, Newberg, Oregon

Status

Recruiting

Address

Providence Newberg Medical Center

Newberg, Oregon, 97132

Site Contact

Site Public Contact

[email protected]

503-215-2614

Providence Portland Medical Center, Portland, Oregon

Status

Recruiting

Address

Providence Portland Medical Center

Portland, Oregon, 97213

Site Contact

Site Public Contact

[email protected]

503-215-2614

Providence Saint Vincent Medical Center, Portland, Oregon

Status

Recruiting

Address

Providence Saint Vincent Medical Center

Portland, Oregon, 97225

Site Contact

Site Public Contact

[email protected]

503-215-2614

UPMC Altoona, Altoona, Pennsylvania

Status

Recruiting

Address

UPMC Altoona

Altoona, Pennsylvania, 16601

Site Contact

Site Public Contact

[email protected]

Beaver, Pennsylvania

Status

Recruiting

Address

UPMC-Heritage Valley Health System Beaver

Beaver, Pennsylvania, 15009

Site Contact

Site Public Contact

[email protected]

412-389-5208

Butler, Pennsylvania

Status

Recruiting

Address

UPMC Hillman Cancer Center at Butler Health System

Butler, Pennsylvania, 16001

Site Contact

Site Public Contact

[email protected]

412-389-5208

UPMC Camp Hill, Camp Hill, Pennsylvania

Status

Active, not recruiting

Address

UPMC Camp Hill

Camp Hill, Pennsylvania, 17011

Carlisle Regional Cancer Center, Carlisle, Pennsylvania

Status

Recruiting

Address

Carlisle Regional Cancer Center

Carlisle, Pennsylvania, 17015

Site Contact

Site Public Contact

[email protected]

Cranberry Township, Pennsylvania

Status

Recruiting

Address

UPMC Hillman Cancer Center - Passavant - Cranberry

Cranberry Township, Pennsylvania, 16066

Site Contact

Site Public Contact

[email protected]

412-389-5208

UPMC Hillman Cancer Center Erie, Erie, Pennsylvania

Status

Recruiting

Address

UPMC Hillman Cancer Center Erie

Erie, Pennsylvania, 16505

Site Contact

Site Public Contact

[email protected]

412-389-5208

UPMC Cancer Center at UPMC Horizon, Farrell, Pennsylvania

Status

Recruiting

Address

UPMC Cancer Center at UPMC Horizon

Farrell, Pennsylvania, 16121

Site Contact

Site Public Contact

[email protected]

Greensburg, Pennsylvania

Status

Recruiting

Address

UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg, Pennsylvania, 15601

Site Contact

Site Public Contact

724-838-1900

Oncology Hematology Associates, Greenville, Pennsylvania

Status

Recruiting

Address

Oncology Hematology Associates

Greenville, Pennsylvania, 16125

Site Contact

Site Public Contact

[email protected]

Greenville, Pennsylvania

Status

Suspended

Address

UPMC Hillman Cancer Center in Greenville/UPMC Horizon

Greenville, Pennsylvania, 16125

Harrisburg, Pennsylvania

Status

Recruiting

Address

UPMC Pinnacle Cancer Center/Community Osteopathic Campus

Harrisburg, Pennsylvania, 17109

Site Contact

Site Public Contact

[email protected]

717-724-6765

IRMC Cancer Center, Indiana, Pennsylvania

Status

Recruiting

Address

IRMC Cancer Center

Indiana, Pennsylvania, 15701

Site Contact

Site Public Contact

[email protected]

412-389-5208

Johnstown, Pennsylvania

Status

Recruiting

Address

UPMC-Johnstown/John P. Murtha Regional Cancer Center

Johnstown, Pennsylvania, 15901

Site Contact

Site Public Contact

814-534-4724

UPMC Cancer Center at UPMC McKeesport, McKeesport, Pennsylvania

Status

Recruiting

Address

UPMC Cancer Center at UPMC McKeesport

McKeesport, Pennsylvania, 15132

Site Contact

Site Public Contact

412-647-8073

Mechanicsburg, Pennsylvania

Status

Recruiting

Address

UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

Mechanicsburg, Pennsylvania, 17050

Site Contact

Site Public Contact

[email protected]

412-389-5208

Forbes Hospital, Monroeville, Pennsylvania

Status

Recruiting

Address

Forbes Hospital

Monroeville, Pennsylvania, 15146

Site Contact

Site Public Contact

412-858-7746

UPMC Hillman Cancer Center - Monroeville, Monroeville, Pennsylvania

Status

Recruiting

Address

UPMC Hillman Cancer Center - Monroeville

Monroeville, Pennsylvania, 15146

Site Contact

Site Public Contact

[email protected]

412-389-5208

UPMC Hillman Cancer Center in Coraopolis, Moon, Pennsylvania

Status

Recruiting

Address

UPMC Hillman Cancer Center in Coraopolis

Moon, Pennsylvania, 15108

Site Contact

Site Public Contact

[email protected]

412-389-5208

Mount Pleasant, Pennsylvania

Status

Recruiting

Address

UPMC Hillman Cancer Center - Part of Frick Hospital

Mount Pleasant, Pennsylvania, 15666

Site Contact

Site Public Contact

[email protected]

412-389-5208

N. Huntingdon, Pennsylvania

Status

Recruiting

Address

Arnold Palmer Cancer Center Medical Oncology Norwin

N. Huntingdon, Pennsylvania, 15642

Site Contact

Site Public Contact

[email protected]

412-389-5208

UPMC Cancer Center-Natrona Heights, Natrona Heights, Pennsylvania

Status

Recruiting

Address

UPMC Cancer Center-Natrona Heights

Natrona Heights, Pennsylvania, 15065

Site Contact

Site Public Contact

724-230-3030

UPMC Hillman Cancer Center - New Castle, New Castle, Pennsylvania

Status

Recruiting

Address

UPMC Hillman Cancer Center - New Castle

New Castle, Pennsylvania, 16105

Site Contact

Site Public Contact

[email protected]

412-389-5208

ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania

Status

Recruiting

Address

ECOG-ACRIN Cancer Research Group

Philadelphia, Pennsylvania, 19103

Site Contact

Aarti Bhatia

[email protected]

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Status

Recruiting

Address

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107

Site Contact

Site Public Contact

[email protected]

215-600-9151

Jefferson Torresdale Hospital, Philadelphia, Pennsylvania

Status

Recruiting

Address

Jefferson Torresdale Hospital

Philadelphia, Pennsylvania, 19114

Site Contact

Site Public Contact

[email protected]

215-600-9151

Allegheny General Hospital, Pittsburgh, Pennsylvania

Status

Recruiting

Address

Allegheny General Hospital

Pittsburgh, Pennsylvania, 15212

Site Contact

Site Public Contact

877-284-2000

UPMC-Saint Margaret, Pittsburgh, Pennsylvania

Status

Recruiting

Address

UPMC-Saint Margaret

Pittsburgh, Pennsylvania, 15215

Site Contact

Site Public Contact

412-784-4900

UPMC-Mercy Hospital, Pittsburgh, Pennsylvania

Status

Recruiting

Address

UPMC-Mercy Hospital

Pittsburgh, Pennsylvania, 15219

Site Contact

Site Public Contact

800-533-8762

Pittsburgh, Pennsylvania

Status

Recruiting

Address

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232

Site Contact

Site Public Contact

412-647-8073

UPMC-Passavant Hospital, Pittsburgh, Pennsylvania

Status

Recruiting

Address

UPMC-Passavant Hospital

Pittsburgh, Pennsylvania, 15237

Site Contact

Site Public Contact

412-367-6454

UPMC-Saint Clair Hospital Cancer Center, Pittsburgh, Pennsylvania

Status

Recruiting

Address

UPMC-Saint Clair Hospital Cancer Center

Pittsburgh, Pennsylvania, 15243

Site Contact

Site Public Contact

412-502-3920

UPMC Cancer Center at UPMC Northwest, Seneca, Pennsylvania

Status

Recruiting

Address

UPMC Cancer Center at UPMC Northwest

Seneca, Pennsylvania, 16346

Site Contact

Site Public Contact

814-676-7900

UPMC Cancer Center-Uniontown, Uniontown, Pennsylvania

Status

Recruiting

Address

UPMC Cancer Center-Uniontown

Uniontown, Pennsylvania, 15401

Site Contact

Site Public Contact

[email protected]

UPMC Cancer Center-Washington, Washington, Pennsylvania

Status

Recruiting

Address

UPMC Cancer Center-Washington

Washington, Pennsylvania, 15301

Site Contact

Site Public Contact

[email protected]

West Mifflin, Pennsylvania

Status

Recruiting

Address

UPMC West Mifflin-Cancer Center Jefferson

West Mifflin, Pennsylvania, 15122

Site Contact

Site Public Contact

412-653-8100

Divine Providence Hospital, Williamsport, Pennsylvania

Status

Recruiting

Address

Divine Providence Hospital

Williamsport, Pennsylvania, 17754

Site Contact

Site Public Contact

[email protected]

Asplundh Cancer Pavilion, Willow Grove, Pennsylvania

Status

Recruiting

Address

Asplundh Cancer Pavilion

Willow Grove, Pennsylvania, 19090

Site Contact

Site Public Contact

[email protected]

215-600-9151

UPMC Memorial, York, Pennsylvania

Status

Recruiting

Address

UPMC Memorial

York, Pennsylvania, 17408

Site Contact

Site Public Contact

717-724-6760

Westerly, Rhode Island

Status

Recruiting

Address

Smilow Cancer Hospital Care Center - Westerly

Westerly, Rhode Island, 02891

Site Contact

Site Public Contact

[email protected]

203-785-5702

Thompson Cancer Survival Center, Knoxville, Tennessee

Status

Active, not recruiting

Address

Thompson Cancer Survival Center

Knoxville, Tennessee, 37916

Thompson Cancer Survival Center - West, Knoxville, Tennessee

Status

Active, not recruiting

Address

Thompson Cancer Survival Center - West

Knoxville, Tennessee, 37932

Thompson Oncology Group-Lenoir City, Lenoir City, Tennessee

Status

Active, not recruiting

Address

Thompson Oncology Group-Lenoir City

Lenoir City, Tennessee, 37772

Nashville, Tennessee

Status

Recruiting

Address

Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232

Site Contact

Site Public Contact

800-811-8480

Thompson Oncology Group-Oak Ridge, Oak Ridge, Tennessee

Status

Active, not recruiting

Address

Thompson Oncology Group-Oak Ridge

Oak Ridge, Tennessee, 37830

Dartmouth Cancer Center - North, Saint Johnsbury, Vermont

Status

Suspended

Address

Dartmouth Cancer Center - North

Saint Johnsbury, Vermont, 05819

Charleston, West Virginia

Status

Recruiting

Address

West Virginia University Charleston Division

Charleston, West Virginia, 25304

Site Contact

Site Public Contact

304-388-9944

ProHealth D N Greenwald Center, Mukwonago, Wisconsin

Status

Recruiting

Address

ProHealth D N Greenwald Center

Mukwonago, Wisconsin, 53149

Site Contact

Site Public Contact

[email protected]

ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin

Status

Recruiting

Address

ProHealth Oconomowoc Memorial Hospital

Oconomowoc, Wisconsin, 53066

Site Contact

Site Public Contact

262-928-7878

UW Cancer Center at ProHealth Care, Waukesha, Wisconsin

Status

Recruiting

Address

UW Cancer Center at ProHealth Care

Waukesha, Wisconsin, 53188

Site Contact

Site Public Contact

[email protected]

262-928-5539

Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with a healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with site contacts or other relevant parties. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage trial participants to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.